Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (6956)	7/29/1999 3:37:00 PM
From: PartyTime	Respond to of 9719

Any thoughts on NTOP? Thanks. Also, what's happening with WSTL?

To: Harold Engstrom who wrote (6956)	7/29/1999 8:56:00 PM
From: Vector1	Respond to of 9719

<<Why aren't more people excited about this?>> Good question. CLTR is currently conducting a trial with Bexxar in conjunction with Fludarabine Chemo therapy as a first line treatment. The data should be available at ASH in December. In theory by first dosing with Fludarabine the patients immune system is weakened making the likelihood of a HAMA response much lower. Imagine the value of CLTR if the results at ASH show very low HAMA and over 75% complete response. I think results like that are a real POSSIBILITY based on the efficacy we have seen in Bexxar in the past. V1